This product will be manufactured at Lupin’s Aurangabad facility in India. to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation for treatment of deep vein thrombosis ...

Lupin Limited announced on Tuesday that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing ...

New Delhi: Drug firm Lupin on Monday said the US health regulator has completed inspection of its Aurangabad facility in Maharashtra without any observation. The inspection was carried out by the ...

Healthcare & Pharmaceuticalscategory US Supreme Court largely backs FDA's denial of flavored vape product applications 3:42 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory US Supreme ...

Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...

Boeing is nearing a potential sale of some two dozen 777X jets to Korean Air in a roughly $4 billion to $6 billion deal that could be finalised as early as July's Farnborough Airshow, industry ...

Pharma major Lupin Ltd has received Establishment Inspection Report (EIR) from the US Food and Drug Administration for its Aurangabad facility. The inspection for the facility was carried out by ...

New Delhi, Aug 21 (PTI) Drug firm Lupin today said it has received establishment inspection report (EIR) from the US health regulator for its Aurangabad plant in Maharashtra. It has received ...

USFDA makes eight observations after Lupin’s Aurangabad unit visit The facility was recently inspected by the United States Food and Drug Administration (USFDA). The inspection was completed on ...

Drug maker Lupin on May 15 said it has received three observations from the US health regulator for its Aurangabad-based manufacturing facility. The US Food and Drug Administration (USFDA ...

Lupin on Wednesday said it has received three observations from the US health regulator for its Aurangabad-based manufacturing facility. The US Food and Drug Administration (USFDA) carried out the ...

This product will be produced at Lupin’s Aurangabad facility in India. In early 2025, Lupin secured approval from the agency for its Sacubitril and Valsartan tablets to treat heart failure.